ArticleComputational and structural biotechnology journal2021
Subtypes identification on heart failure with preserved ejection fraction via network enhancement fusion using multi-omics data.
Article in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Pooled it
- DNA methylation and cardiovascular disease in humans: a systematic review and database of known CpG methylation sites.Clinical epigenetics · 2023Pooled it
- Global and regional DNA methylation patterns in heart failure: a case-control analysis.EBioMedicine · 2026Article
- A metagene based similarity network fusion approach for multi-omics data integration identified novel subtypes in renal cell carcinoma.Briefings in bioinformatics · 2024Article
- Similarity network fusion to identify phenotypes of small-for-gestational-age fetuses.iScience · 2023Article
- Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction.Biomedicines · 2023Article
- Phenomics and Robust Multiomics Data for Cardiovascular Disease Subtyping.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Multiomics Network Medicine Approaches to Precision Medicine and Therapeutics in Cardiovascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions.Cardiovascular research · 2023Review
- Article
- Regulatory mechanism of fibrosis-related genes in patients with heart failure.Frontiers in genetics · 2022Article
- Identifying novel subgroups in heart failure patients with unsupervised machine learning: A scoping review.Frontiers in cardiovascular medicine · 2022Article
- Multi-omics data integration for subtype identification of Chinese lower-grade gliomas: A joint similarity network fusion approach.Computational and structural biotechnology journal · 2022Article
- Predicting readmission rates in critically ill heart failure patients during a 90-day vulnerable phase using interpretable machine learning models.Clinics (Sao Paulo, Brazil)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is associated with multiple etiologic and pathophysiologic factors. HFpEF leads to significant cardiovascular morbidity and mortality. There are various reasons that fail to identify effective therapeutic interventions for HFpEF, primarily due to its clinical heterogeneity causing significant difficulties in determining physiologic and prognostic implications for this syndrome. Thus, identifying clinical subtypes using multi-omics data has great implications for efficient treatment and prognosis of HFpEF patients. Here we proposed to integrate mRNA, DNA methylation and microRNA (miRNA) expression data of HFpEF with a similarity network fusion (SNF) method following a network enhancement (ne-SNF) denoising technique to form a fused network. A spectral clustering method was then used to obtain clusters of patient subtypes. Experiments on HFpEF datasets demonstrated that ne-SNF significantly outperforms single data subtype analysis and other integrated methods. The identified subgroups were shown to have statistically significant differences in survival. Two HFpEF subtypes were defined: a high-risk group (16.8%) and a low-risk group (83.2%). The 5-year mortality rates were 63.3% and 33.0% for the high- and low-risk group, respectively. After adjusting for the effects of clinical covariates, HFpEF patients in the high-risk group were 2.43 times more likely to die than the low-risk group. A total of 157 differentially expressed (DE) mRNAs, 2199 abnormal methylations and 121 DE miRNAs were identified between two subtypes. They were also enriched in many HFpEF-related biological processes or pathways. The ne-SNF method provides a novel pipeline for subtype identification in integrated analysis of multi-omics data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.